A Dark Vector Cognition product

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

52K characters. Original on sec.gov ·

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The 18 tables in Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations as one CSV, figures in aligned columns. For subscribers: paste your API key. One API call. Plans from $19 a month, see pricing.

Special Note Regarding Forward-Looking Statements

This report contains or may contain certain forward-looking statements and information that are based on the beliefs of our management as well as estimates and assumptions made by, and information currently available to, our management. All statements other than statements regarding historical facts are forward-looking statements. The words “believe,” “expect,” “intend,” “anticipate,” “will continue,” “will,” “estimate,” “plan,” “future” and other similar expressions, and negative statements of such expressions, generally identify forward-looking statements, including, in particular, statements regarding expectations of future revenue or earnings, expenses, results of operations, new product development, new product launches, new markets for our products, the integration of acquisitions and success of strategic initiatives, including divestitures, our supply chain, domestic and international regulatory developments, litigation, tax outlook, and the expected impact of macroeconomic conditions on our business. These forward-looking statements are made in accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements reflect the views of our management at the time the statements are made and are subject to a number of risks, uncertainties, estimates and assumptions, including, without limitation, and in addition to those identified in the text surrounding such statements, those identified in our Annual Report on Form 10-K for the fiscal year ended June 30, 2026 and elsewhere in this report. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market, and other data from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data, and similar sources.

In addition, important factors to consider in evaluating such forward-looking statements include changes or developments in healthcare reform, social, macroeconomic, market, legal or regulatory circumstances, including the impact of public health crises; changes in our business or growth strategy or an inability to execute our strategy due to changes in our industry or the economy generally, the emergence of new or growing competitors, disruptions and delays in the supply chain, the actions or omissions of third parties, including suppliers, customers, competitors and governmental authorities, geopolitical and economic conditions in foreign jurisdictions impacting our business, including the direct or indirect effect of new or increased tariffs, the indirect costs associated with global trade disruption and various other factors. If any one or more of these risks or uncertainties materialize, or underlying estimates or assumptions prove incorrect, actual results may vary significantly from those expressed in our forward-looking statements, and there can be no assurance that the forward-looking statements contained in this report will in fact occur.

Before deciding to purchase, hold or sell our common stock, you should carefully consider the risks described in our Annual Report on Form 10-K for the fiscal year ended June 30, 2026, in addition to the other cautionary statements and risks described elsewhere in this report and in our other filings with the Securities and Exchange Commission, or the SEC, including our subsequent reports on Forms 10-Q and 8-K. These risks and uncertainties are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our business. If any of these known or unknown risks or uncertainties actually occurs with material adverse effects on us, our business, financial condition and results of operations could be seriously harmed. In that event, the market price for our common stock will likely decline and you may lose all or part of your investment.

PART I – FINANCIAL INFORMATIONItem 2

RESMED INC. AND SUBSIDIARIES

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

The following is an overview of our results of operations for the three months ended September 30, 2026. Management’s discussion and analysis of financial condition and results of operations, or the MD&A, is intended to help the reader understand our results of operations and financial condition. It is provided as a supplement to, and should be read in conjunction with, the condensed consolidated financial statements and notes included in this report.

We are a global leader in digital health and cloud-connected medical devices. We design innovative technology with the intention to empower people to live happier, healthier lives. Our artificial intelligence, or AI, powered digital health solutions, cloud-connected devices and intelligent software are designed to make home healthcare more personalized, accessible and effective. By enabling better care, our products seek to improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems.

Since the development of continuous positive airway pressure therapy, we have expanded our business by developing or acquiring a number of innovative products and solutions for a broad range of sleep and related breathing health disorders including technologies to be applied in medical and consumer products, life support and ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, and dental devices. In addition, we are a leading provider of cloud-based health applications, software and devices designed to provide connected care, enabling clinicians to manage more patients efficiently and effectively, as well as enabling and encouraging patients’ long-term adherence to and satisfaction with their therapy. Our growth has been fueled by geographic expansion, our research and product development efforts, acquisitions and an increasing awareness of sleep and related breathing health conditions, like chronic obstructive pulmonary disease, as significant health concerns.

We are committed to ongoing investment in research and development and product enhancements. During the three months ended September 30, 2026, we invested $103 million on research and development activities, which represents 7.3% of net revenues, with a continued focus on the development and commercialization of new, innovative products and solutions that improve patient outcomes, create efficiencies for our customers and help physicians and providers better manage chronic disease and lower healthcare costs. For example, our newest device, AirSense 11, introduced new features such as a touch screen, algorithms for patients new to therapy, digital enhancements, and over-the-air update capabilities. Our operations include residential care software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. These platforms, together with our cloud-based remote monitoring and therapy management system and robust product pipeline, should continue to provide a strong foundation for future growth.

We have determined that we have two operating segments, which are the sleep and respiratory disorders sector of the medical device industry, or Sleep and Breathing Health, and the supply of business management software as a service to residential healthcare providers, or Residential Care Software.

On September 1, 2026, we completed the previously announced sale of our MatrixCare business. The transaction was undertaken as part of our portfolio optimization strategy to increase focus on our core growth areas of sleep, breathing, and connected home-based healthcare. The transaction does not represent a strategic shift that has a major effect on our operations or financial results. Accordingly, the results of the MatrixCare business through the date of disposition and the associated gain on divestiture are presented within continuing operations. The operating results of the MatrixCare business through the date of disposition are also included within the Residential Care Software segment. See Note 13 to the unaudited condensed consolidated financial statements for additional information.

During the first quarter of fiscal year 2027, we revised the presentation of restructuring expenses and amortization of acquired intangibles in our condensed consolidated statements of operations. Restructuring expenses, which were previously presented as a separate line item within operating expenses, are now classified within cost of sales, research and development expenses, and selling, general and administrative expenses based on the function of the associated costs. Amortization of acquired intangibles relating to cost of sales is no longer presented as a separate line item within cost of sales. Amortization of acquired intangibles relating to operating expenses are now classified within selling, general and administrative expenses. Prior-period amounts have been reclassified to conform to the current-period presentation. The reclassifications had no effect on previously reported income from operations, income before income taxes, net income, earnings per share or cash flows. See Note 1 to the unaudited condensed consolidated financial statements for additional information.

PART I – FINANCIAL INFORMATIONItem 2

RESMED INC. AND SUBSIDIARIES

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Net revenue for the three months ended September 30, 2026 was $1.4 billion, an increase of 6% compared to the three months ended September 30, 2025. Gross margin was 61.5% for the three months ended September 30, 2026 compared to 61.2% for the three months ended September 30, 2025. Diluted earnings per share was $2.92 for the three months ended September 30, 2026, compared to diluted earnings per share of $2.37 for the three months ended September 30, 2025.

At September 30, 2026, our cash and cash equivalents totaled $1.0 billion, our total assets were $8.2 billion and our stockholders’ equity was $5.9 billion.

In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency” basis, which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with accounting principles generally accepted in the United States, or GAAP.

Results of Operations

Three Months Ended September 30, 2026 Compared to the Three Months Ended September 30, 2025

Net Revenue

Net revenue for the three months ended September 30, 2026 increased to $1,415 million from $1,336 million for the three months ended September 30, 2025, an increase of $79 million or 6% (a 6% increase on a constant currency basis and a 7% increase on a core constant currency basis). The following table summarizes our net revenue disaggregated by segment, product and region (in thousands):

Three Months Ended September 30,% ChangeConstant Currency**(1)**Core Constant Currency**(2)**
20262025
Americas
Devices$436,438$413,4386%6%4%
Masks and other396,981361,316101010
Total Americas$833,419$774,7548%8%7%
Rest of World
Devices$283,854$266,8726%6%6%
Masks and other142,529127,820121111
Total Rest of World$426,383$394,6928%8%8%
Global revenue
Devices$720,292$680,3106%6%5%
Masks and other539,510489,136101010
Total Sleep and Breathing Health$1,259,802$1,169,4468%8%7%
Residential Care Software155,012166,136(7)%(6)%5%
Total$1,414,814$1,335,5826%6%7%

1.Constant currency numbers exclude the impact of movements in international currencies.

2.Core constant currency numbers exclude the impact of movements in international currencies and the impact of acquisitions and divestitures. See Summary of Non-GAAP Financial Measures below.

Sleep and Breathing Health

Net revenue from our Sleep and Breathing Health business for the three months ended September 30, 2026 was $1,260 million, an increase of 8% compared to net revenue for the three months ended September 30, 2025. Movements in international currencies against the U.S. dollar had a negligible impact on net revenue for the three months ended September 30, 2026. Excluding the impact of currency movements, total Sleep and Breathing Health net revenue for the

PART I – FINANCIAL INFORMATIONItem 2

RESMED INC. AND SUBSIDIARIES

Management’s Discussion and Analysis of Financial Condition and Results of Operations

three months ended September 30, 2026 increased by 8% compared to the three months ended September 30, 2025. The increase in net revenue associated with our devices and masks was primarily attributable to increased demand and unit sales across our sleep health portfolio, partially offset by lower unit sales of our life support devices primarily reflecting the planned discontinuation of our Astral device.

Net revenue from our Sleep and Breathing Health business in the Americas for the three months ended September 30, 2026 increased to $833 million from $775 million for the three months ended September 30, 2025, an increase of $59 million or 8%. The increase in net revenue associated with our devices and masks was primarily attributable to increased demand and unit sales.

Net revenue from our Sleep and Breathing Health business in Rest of World increased for the three months ended September 30, 2026 to $426 million from $395 million for the three months ended September 30, 2025, an increase of $32 million or 8% (an 8% increase on a constant currency basis). The constant currency increase in device and mask sales in Rest of World was primarily attributable to increased demand and unit sales across our sleep health portfolio including the impact of device fleet renewals in France, partially offset by lower unit sales of our life support devices primarily reflecting the planned discontinuation of our Astral device.

Net revenue from devices for the three months ended September 30, 2026 increased to $720 million from $680 million for the three months ended September 30, 2025, an increase of $40 million or 6%, including an increase of 6% in the Americas and an increase of 6% in Rest of World (a 6% increase on a constant currency basis). Excluding the impact of foreign currency movements, device sales for the three months ended September 30, 2026 increased by 6%.

Net revenue from masks and other for the three months ended September 30, 2026 increased to $540 million from $489 million for the three months ended September 30, 2025, an increase of $50 million or 10%, including an increase of 10% in the Americas and an increase of 12% in Rest of World (an 11% increase on a constant currency basis). Excluding the impact of foreign currency movements, masks and other sales for the three months ended September 30, 2026 increased by 10%.

Residential Care Software

Net revenue from our Residential Care Software business for the three months ended September 30, 2026 decreased to $155 million from $166 million for the three months ended September 30, 2025, a decrease of $11 million or 7%. Movements in international currencies against the U.S. dollar negatively impacted net revenue by approximately $1 million for the three months ended September 30, 2026. Excluding the impact of foreign currency movements, net revenue from our Residential Care Software business for the three months ended September 30, 2026 decreased by 6% compared to the three months ended September 30, 2025. The decrease was predominantly due to the sale of our MatrixCare business, which closed on September 1, 2026, partially offset by growth in our MEDIFOX DAN and Brightree verticals.

Gross Profit and Gross Margin

Gross profit increased for the three months ended September 30, 2026 to $871 million from $818 million for the three months ended September 30, 2025, an increase of $53 million or 6%. Gross margin, which is gross profit as a percentage of net revenue, for the three months ended September 30, 2026 was 61.5% compared to 61.2% for the three months ended September 30, 2025.

The increase in gross margin for the three months ended September 30, 2026 compared to the three months ended September 30, 2025 was due primarily to manufacturing and logistics efficiencies, component cost improvements, and lower amortization of acquired intangible assets following the sale of our MatrixCare business, partially offset by higher restructuring and business transformation costs. These costs were $8 million during the three months ended September 30, 2026, primarily associated with professional fees related to supply chain processes and systems transformation initiatives, compared to $3 million during the three months ended September 30, 2025 associated with workforce planning activities. We continue to experience inflationary pressure on our manufacturing inputs, particularly electronic components, and expect these pressures to continue through the remainder of fiscal year 2027. Additionally, we are strategically expanding parts of our supply chain, which may result in fluctuations in our gross margin as we activate new sites or expand existing sites.

PART I – FINANCIAL INFORMATIONItem 2

RESMED INC. AND SUBSIDIARIES

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Operating Expenses

The following table summarizes our operating expenses (in thousands):

Three Months Ended September 30,Change% ChangeConstant Currency
20262025
Research and development$102,860$89,479$13,38115%13%
as a % of net revenue7.3%6.7%
Selling, general, and administrative$314,723$281,648$33,07512%11%
as a % of net revenue22.2%21.1%

Research and Development Expenses

Research and development expenses increased for the three months ended September 30, 2026 to $103 million from $89 million for the three months ended September 30, 2025, an increase of $13 million or 15%. Research and development expenses were unfavorably impacted by the movement of international currencies against the U.S. dollar, which increased our expenses by approximately $2 million for the three months ended September 30, 2026, as reported in U.S. dollars. Excluding the impact of foreign currency movements, research and development expenses increased by 13% compared to the three months ended September 30, 2025. As a percentage of net revenue, research and development expenses were 7.3% for the three months ended September 30, 2026 and 6.7% for the three months ended September 30, 2025.

The increase in research and development expenses during the three months ended September 30, 2026 compared to the three months ended September 30, 2025 was primarily due to increases in employee-related costs.

Selling, General, and Administrative Expenses

Selling, general, and administrative expenses increased for the three months ended September 30, 2026 to $315 million from $282 million for the three months ended September 30, 2025, an increase of $33 million or 12%. Selling, general, and administrative expenses were unfavorably impacted by the movement of international currencies against the U.S. dollar, which increased our expenses by approximately $2 million, as reported in U.S. dollars. Excluding the impact of foreign currency movements, selling, general, and administrative expenses for the three months ended September 30, 2026 increased by 11% compared to the three months ended September 30, 2025. As a percentage of net revenue, selling, general, and administrative expenses were 22.2% for the three months ended September 30, 2026, compared to 21.1% for the three months ended September 30, 2025.

The constant currency increase in selling, general, and administrative expenses during the three months ended September 30, 2026 compared to the three months ended September 30, 2025 was partially due to additional expenses associated with our acquisition of Noctrix, employee-related costs, and marketing investments. We also initiated several growth and transformation initiatives resulting in restructuring and business transformation costs of $20 million during the three months ended September 30, 2026, compared to $10 million associated with workforce planning activities during the three months ended September 30, 2025. Additionally, during the three months ended September 30, 2026, we recorded $10 million of acquisition and divestment-related expenses primarily associated with the sale of the MatrixCare business. We did not incur acquisition and divestment-related expenses during the three months ended September 30, 2025. These increases were partially offset by a decrease in amortization of acquired intangibles of $3.6 million related to the cessation of amortization for intangible assets associated with the MatrixCare business upon its classification as held for sale on June 30, 2026, as well as certain intangible assets reaching the end of their useful lives and becoming fully amortized.

PART I – FINANCIAL INFORMATIONItem 2

RESMED INC. AND SUBSIDIARIES

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Total Other Income (Loss), Net

The following table summarizes our other income (loss) (in thousands):

Three Months Ended September 30,
20262025Change
Interest income$21,198$15,914$5,284
Interest expense(4,814)(7,121)2,307
Gain (loss) attributable to equity method investments1,8841,489395
Gain (loss) on equity investments5,719(6,190)11,909
Gain on divestment of subsidiaries61,784—61,784
Other, net400(3,836)4,236
Total other income (loss), net$86,171$256$85,915

Total other income (loss), net for the three months ended September 30, 2026 was income of $86 million compared to income of $0.3 million for the three months ended September 30, 2025. The increase was primarily due to a $62 million gain recognized upon the divestment of the MatrixCare business on September 1, 2026. In addition, interest income increased to $21 million for the three months ended September 30, 2026 compared to $16 million for the three months ended September 30, 2025 due to gains recognized on cross-currency swaps associated with our fair value and net investment hedges. Interest expense decreased to $5 million for the three months ended September 30, 2026 compared to $7 million for the three months ended September 30, 2025 due to lower debt levels following repayments on our term credit facility and senior notes. We also recognized a gain associated with our equity investments of $6 million for the three months ended September 30, 2026 compared to a loss of $6 million for the three months ended September 30, 2025.

Income Taxes

Our effective income tax rate for the three months ended September 30, 2026 was 22.4% as compared to 22.0% for the three months ended September 30, 2025. Our effective rate of 22.4% for the three months ended September 30, 2026 differs from the statutory rate of 21.0% primarily due to foreign operations, research credits and discrete tax adjustments. The increase in our effective tax rate for the three months ended September 30, 2026 was primarily due to the impact of global minimum taxes implemented in accordance with Pillar Two and discrete tax adjustments.

Our Singapore operations operate under certain tax holidays and tax incentive programs that will expire in whole or in part at various dates through June 30, 2030. As a result of the U.S. Tax Cuts and Jobs Act of 2017, we treated all non-U.S. historical earnings as taxable during the year ended June 30, 2018. Therefore, future repatriation of cash held by our non-U.S. subsidiaries will generally not be subject to U.S. federal tax, if repatriated.

The Organization of Economic Co-operation and Development, or the OECD, and the G20 Inclusive Framework on Base Erosion and Profit Shifting, or the Inclusive Framework, has put forth two proposals—Pillar One and Pillar Two—that (i) revise the existing profit allocation and nexus rules and (ii) ensure a minimal level of taxation, respectively. Effective in our fiscal year beginning July 1, 2024, various jurisdictions in which we operate began implementing the global minimum tax prescribed under Pillar Two. Pillar Two legislation in effect as of September 30, 2026 has been incorporated into our condensed consolidated financial statements.

On January 1, 2026, the OECD released the Side-by-Side, or SbS, Package, which exempts U.S.-headquartered multinational enterprises from Pillar Two’s income inclusion and undertaxed profits rules for tax years beginning on or after January 1, 2026. The remaining OECD countries are in the process of implementing the SbS Package in local legislation to align with the OECD framework. We are continuing to evaluate the potential impacts of the Inclusive Framework for future periods.

Net Income and Earnings per Share

As a result of the factors above, our net income for the three months ended September 30, 2026 was $418 million compared to $349 million for the three months ended September 30, 2025, an increase of $70 million or 20%.

PART I – FINANCIAL INFORMATIONItem 2

RESMED INC. AND SUBSIDIARIES

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Our diluted earnings per share for the three months ended September 30, 2026 was $2.92 per diluted share compared to $2.37 for the three months ended September 30, 2025, an increase of $0.55 or 23%.

Summary of Non-GAAP Financial Measures

In addition to financial information prepared in accordance with GAAP, our management uses certain non-GAAP financial measures, such as non-GAAP core constant currency basis, non-GAAP gross profit, non-GAAP gross margin, non-GAAP income from operations, non-GAAP operating margin, non-GAAP net income, and non-GAAP diluted earnings per share, in evaluating the performance of our business. We believe that these non-GAAP financial measures, when reviewed in conjunction with GAAP financial measures, can provide investors better insight when evaluating our performance from core operations and can provide more consistent financial reporting across periods. For these reasons, we use non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. These non-GAAP financial measures should be considered in addition to, and not superior to or as a substitute for, GAAP financial measures. We strongly encourage investors and shareholders to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure. Non-GAAP financial measures as presented herein may not be comparable to similarly titled measures used by other companies.

We adjust for the following items when calculating our non-GAAP measures:

  • Acquisitions and divestitures: Revenue associated with acquisitions that have not been owned for a full year or revenue associated with subsidiaries that have been divested in the current fiscal year have been excluded when calculating revenue on a core constant currency basis.

  • Amortization of acquired intangibles: Amortization of acquired intangible assets has been excluded from cost of sales, operating expenses and related non-GAAP measures.

  • Restructuring and business transformation costs: Restructuring charges primarily include employee severance and one-time termination costs in connection with certain growth and transformation initiatives, in addition to ongoing workforce planning activities. Business transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits that do not meet the definition of restructuring charges.

  • Acquisition and divestment-related expenses: These expenses include transaction, consultancy and professional fees associated with the acquisition or divestiture of subsidiaries.

  • Gain on divestment of subsidiaries: This reflects the non-recurring gain recognized upon the divestiture of our MatrixCare business.

  • Income tax effect of interest income on tax penalties: This reflects the net impact of non-recurring interest and penalties refunded from the IRS due to amended returns.

  • The tax effects of all non-tax adjustments above.

Non-GAAP measures are reconciled to their most directly comparable GAAP financial measures below (in thousands, except percentages and per share amounts):

Three Months Ended
September 30, 2026September 30, 2025
GAAP total revenue growth6%9%
Impact of:
Acquisitions/divestitures1—
Effect of foreign currency fluctuations—(1)
Non-GAAP core constant currency total revenue growth7%8%
PART I – FINANCIAL INFORMATIONItem 2

RESMED INC. AND SUBSIDIARIES

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Three Months Ended September 30, 2026
Gross profitResearch and development expensesSelling, general, and administrative expensesIncome from operationsTotal other income (loss), netIncome tax expenseNet incomeDiluted earnings per share
GAAP$870,567$102,860$314,723$452,984$86,171$120,742$418,413$2.92
Amortization of acquired intangibles5,221—(8,317)13,538—3,8339,7050.07
Restructuring and business transformation expenses7,800(1,330)(20,327)29,457—7,02922,4280.16
Acquisition and divestment related expenses——(10,198)10,198——10,1980.07
Gain on divestment of subsidiary————(61,784)(6,863)(54,921)(0.38)
Income tax effect of interest income on tax refunds—————(12,187)12,1870.07
Non-GAAP$883,588$101,530$275,881$506,177$24,387$112,554$418,010$2.91
Three Months Ended September 30, 2025
Gross profitResearch and development expensesSelling, general, and administrative expensesIncome from operationsTotal other income (loss), netIncome tax expenseNet incomeDiluted earnings per share
GAAP$817,664$89,479$281,648$446,537$256$98,257$348,536$2.37
Amortization of acquired intangibles7,821—(11,956)19,777—5,21014,5670.10
Restructuring and business transformation expenses3,156(2,156)(10,498)15,810—4,03811,7720.08
Non-GAAP$828,641$87,323$259,194$482,124$256$107,505$374,875$2.55

Liquidity and Capital Resources

Our principal sources of liquidity are our existing cash and cash equivalents, cash generated from operations and access to our revolving credit facility. Our primary uses of cash have been for research and development activities, selling and marketing activities, capital expenditures, strategic acquisitions and investments, share repurchases, dividend payments and repayment of debt obligations. We expect that cash provided by operating activities may fluctuate in future periods as a result of several factors, including fluctuations in our operating results, which include supply chain disruptions, working capital requirements and capital deployment decisions.

Our future capital requirements will depend on many factors including our growth rate in net revenue, third-party reimbursement of our products for our customers, the timing and extent of spending to support research development efforts, the expansion of selling, general and administrative activities, the timing of introductions of new products, the expenditures associated with possible future acquisitions and divestitures, investments or other business combination transactions. As we assess inorganic growth strategies, we may need to supplement our internally generated cash flow with outside sources. If we are required to access the debt market, we believe that we will be able to secure reasonable borrowing rates. As part of our liquidity strategy, we will continue to monitor our current level of earnings and cash flow generation as well as our ability to access the market considering those earning levels.

PART I – FINANCIAL INFORMATIONItem 2

RESMED INC. AND SUBSIDIARIES

Management’s Discussion and Analysis of Financial Condition and Results of Operations

As of September 30, 2026 and June 30, 2026, we had cash and cash equivalents of $1.0 billion and $1.5 billion, respectively. Our cash and cash equivalents held within the U.S. at September 30, 2026 and June 30, 2026 were $278 million and $732 million, respectively. Our remaining cash and cash equivalent balances at September 30, 2026 and June 30, 2026, were $733 million and $737 million, respectively. Our cash and cash equivalent balances are held at highly rated financial institutions.

As a result of the U.S. Tax Cuts and Jobs Act of 2017, we treated all non-U.S. historical earnings as taxable, which resulted in additional tax expense of $92 million. The related tax liability, which was payable in installments over eight years, has been fully repaid. Accordingly, future repatriation of cash held by our non-U.S. subsidiaries will generally not be subject to U.S. federal tax if repatriated.

On August 31, 2026, we entered into an accelerated share repurchase agreement, or the ASR Agreement, to repurchase $450 million of our common stock. Pursuant to the ASR Agreement, we paid $450 million and received an initial delivery of 1.6 million shares during the three months ended September 30, 2026, representing an estimated 80 percent of the shares to be purchased under the ASR Agreement based on the $230.87 closing price of our common stock on September 2, 2026. Final settlement of the ASR Agreement is expected to occur no later than December 29, 2026, and will be based on a discount to the volume-weighted average price per share of our common stock over the term of the ASR Agreement. We used a portion of the net proceeds from the sale of the MatrixCare business to fund the payment due under the ASR Agreement.

As of September 30, 2026, we had $1,500 million available for draw down under the revolving credit facility and a combined total of $2,511 million in cash and available liquidity under the revolving credit facility.

We believe that our current sources of liquidity will be sufficient to fund our operations, including expected capital expenditures, for the next 12 months and beyond.

Revolving Credit Agreement, Term Credit Agreement and Senior Notes

On June 29, 2022, we entered into a second amended and restated credit agreement, or as amended from time to time, the Revolving Credit Agreement. The Revolving Credit Agreement, among other things, provided a senior unsecured revolving credit facility of $1,500 million, with an uncommitted option to increase the revolving credit facility by an additional amount equal to the greater of $1,000 million or 1.00 times the EBITDA for the trailing twelve-month measurement period. Additionally, on June 29, 2022, ResMed Pty Limited entered into a Second Amendment to the Syndicated Facility Agreement, or the Term Credit Agreement. The Term Credit Agreement, among other things, provides ResMed Pty Limited a senior unsecured term credit facility of $200 million. The Revolving Credit Agreement and Term Credit Agreement each terminate on June 29, 2027, when all unpaid principal and interest under the loans must be repaid. As of September 30, 2026, we had $1,500 million available for draw down under the revolving credit facility.

On July 10, 2019, we entered into a Note Purchase Agreement with the purchasers to that agreement, in connection with the issuance and sale of $500 million aggregate principal amount of senior notes, consisting of $250 million principal amount of our 3.24% senior notes and $250 million principal amount of our 3.45% senior notes, or collectively referred to as the Senior Notes. The 3.24% senior notes were repaid in full on July 10, 2026. The 3.45% senior notes are due July 10, 2029.

On September 30, 2026, there was a total of $410 million outstanding under the Revolving Credit Agreement, Term Credit Agreement and Senior Notes and we were in compliance with our debt covenants. We expect to satisfy all of our liquidity and remaining long-term debt requirements through a combination of cash on hand, cash generated from operations and debt facilities.

PART I – FINANCIAL INFORMATIONItem 2

RESMED INC. AND SUBSIDIARIES

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Cash Flow Summary

The following table summarizes our cash flow activity (in thousands):

Three Months Ended September 30,
20262025
Net cash provided by (used in) operating activities$422,422$457,321
Net cash provided by (used in) investing activities392,055(52,578)
Net cash provided by (used in) financing activities(1,278,003)(230,274)
Effect of exchange rate changes on cash5,034(71)
Net increase (decrease) in cash and cash equivalents$(458,492)$174,398

Operating Activities

Cash provided by operating activities was $422 million for the three months ended September 30, 2026, compared to cash provided of $457 million for the three months ended September 30, 2025. The $35 million decrease was primarily due to higher working capital requirements, including higher inventory levels partially related to the expansion of our supply chain, during the three months ended September 30, 2026 compared to the three months ended September 30, 2025.

Investing Activities

Cash provided by investing activities was $392 million for the three months ended September 30, 2026, compared to cash used of $53 million for the three months ended September 30, 2025. The $445 million increase was primarily due to proceeds from the divestment of the MatrixCare business and proceeds from the maturity of foreign currency contracts, partially offset by increased purchases of property, plant and equipment and cash used to acquire businesses during the three months ended September 30, 2026.

Financing Activities

Cash used in financing activities was $1,278 million for the three months ended September 30, 2026, compared to cash used of $230 million for the three months ended September 30, 2025. The $1,048 million increase was primarily due to $936 million of treasury stock repurchases during the three months ended September 30, 2026 compared to repurchases of $150 million during the three months ended September 30, 2025. In addition, we repaid $250 million of our Senior Notes during three months ended September 30, 2026, compared to no repayments of debt during the three months ended September 30, 2025.

Dividends

During the three months ended September 30, 2026, we paid cash dividends of $0.66 per common share totaling $95 million. On October 29, 2026, our board of directors declared a cash dividend of $0.66 per common share, to be paid on December 17, 2026, to shareholders of record as of the close of business on November 12, 2026. Future dividends are subject to approval by our board of directors.

Common Stock

On February 21, 2014, our board of directors approved our current share repurchase program, authorizing us to acquire up to an aggregate of 20 million shares of our common stock. Since approval of the share repurchase program in 2014 through September 30, 2026, we have repurchased a total of 15.7 million shares under this repurchase program for an aggregate of $2.4 billion. During the three months ended September 30, 2026, we repurchased 3.6 million shares at a cost of $855 million, including commissions and other incremental transaction costs. Shares that are repurchased are classified as treasury stock and reduce the number of shares of common stock outstanding used in calculating earnings (loss) per share. The share repurchase program may be accelerated, suspended, delayed or discontinued at any time at the discretion of our board of directors. At September 30, 2026, 4.3 million additional shares remain available for us to repurchase under the approved share repurchase program.

PART I – FINANCIAL INFORMATIONItem 2

RESMED INC. AND SUBSIDIARIES

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Critical Accounting Principles and Estimates

The preparation of financial statements in conformity with GAAP requires us to make estimates and judgments that affect our reported amounts of assets and liabilities, revenues and expenses and related disclosures of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, including those related to allowance for doubtful accounts, inventory reserves, warranty obligations, goodwill, potentially impaired assets, intangible assets, income taxes and contingencies.

We state these accounting policies in the notes to the financial statements and at relevant sections in this discussion and analysis. The estimates are based on the information that is currently available to us and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could vary from those estimates under different assumptions or conditions.

For a full discussion of our critical accounting policies, see our Annual Report on Form 10-K for the fiscal year ended June 30, 2026.

Recently Issued Accounting Pronouncements

See Note 1 to the unaudited condensed consolidated financial statements for a description of recently issued accounting pronouncements, including the expected dates of adoption and estimated effects on our results of operations, financial position and cash flows.

Contractual Obligations and Commitments

Other than the repayment of our Senior Notes disclosed above, there have been no material changes outside the ordinary course of business in our outstanding contractual obligations from those disclosed within “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the fiscal year ended June 30, 2026.

Off-Balance Sheet Arrangements

As of September 30, 2026, we are not involved in any significant off-balance sheet arrangements, as described in Instruction 8 to Item 303(b) of Regulation S-K promulgated by the SEC.

PART I – FINANCIAL INFORMATIONItem 3

RESMED INC. AND SUBSIDIARIES

Quantitative and Qualitative Disclosures About Market Risk

Previous: Item 1. Financial Statements · Next: Item 3. Quantitative and Qualitative Disclosures about Market Risk